Global Hodgkins Lymphoma Therapeutics Market 2014-2018
出 版 商：Infiniti Research
出版日期：2014/08/06
頁 數：79頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 2,800 (Multi-User License)
USD 3,500 (Global-User License)
USD 2,800 (Multi-User License)
USD 3,500 (Global-User License)
About Hodgkin's Lymphoma
Hodgkin's Lymphoma (HL) is defined as the cancer of the lymph tissue, which is part of our immune system. The exact etiology of HL is unknown. However, the risk of developing the condition is increased if a person suffers from a medical condition that weakens the immune system. In HL, cells in the lymphatic system grow unusually and may spread beyond the lymphatic system. The infection-fighting properties of the lymphocytes are lost, making the person more susceptible to infection. The main treatments used are chemotherapy, followed by radiotherapy or chemotherapy alone. Generally surgery is not used as a treatment for the condition.
TechNavio's analysts forecast the Global Hodgkin's Lymphoma Therapeutics market will grow at a CAGR of 6.84 percent over the period 2013-2018.
Covered in this Report
The Global Hodgkin's Lymphoma Therapeutics market can be divided into eight segments: Alkylating Antineoplastic Agents, Antibiotic Antineoplastic Agents, Antineoplastics Vinca Alkaloid Agents, Podophyllotoxin Derivative Antineoplastic Agents, Antimetabolite Antineoplastic Agents, Anthracycline Antineoplastic Agents, Antimicrotubular Antineoplastics, and Corticosteroids. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of HL that are available in the market.
TechNavio's report, the Global Hodgkin's Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hodgkin's Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ APAC
‧ EMEA
Key Vendors
‧ Bristol Myers Squibb Co.
‧ F. Hoffmann-La Roche Ltd.
‧ Merck & Co. Inc.
‧ Pfizer Inc.
Other Prominent Vendors
‧ 4SC AG
‧ Actinium Pharmaceuticals Inc.
‧ Aeterna Zentaris Inc.
‧ Affimed Therapeutics AG
‧ Hospira Inc.
‧ Incyte Corp.
‧ Novartis AG
‧ Philogen S.p.A.
‧ Seattle Genetics Inc.
‧ Sigma-Tau Pharmaceuticals Inc.
‧ Stemline Therapeutics Inc.
‧ Teva Pharmaceutical Industries Ltd.
Key Market Driver
‧ Improved Diagnostic Techniques.
‧ For a full, detailed list, view our report.
Key Market Challenge
‧ High Cost.
‧ For a full, detailed list, view our report.
Key Market Trend
‧ Increase in Awareness of HL.
‧ For a full, detailed list, view our report.
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
Hodgkin's Lymphoma (HL) is defined as the cancer of the lymph tissue, which is part of our immune system. The exact etiology of HL is unknown. However, the risk of developing the condition is increased if a person suffers from a medical condition that weakens the immune system. In HL, cells in the lymphatic system grow unusually and may spread beyond the lymphatic system. The infection-fighting properties of the lymphocytes are lost, making the person more susceptible to infection. The main treatments used are chemotherapy, followed by radiotherapy or chemotherapy alone. Generally surgery is not used as a treatment for the condition.
TechNavio's analysts forecast the Global Hodgkin's Lymphoma Therapeutics market will grow at a CAGR of 6.84 percent over the period 2013-2018.
Covered in this Report
The Global Hodgkin's Lymphoma Therapeutics market can be divided into eight segments: Alkylating Antineoplastic Agents, Antibiotic Antineoplastic Agents, Antineoplastics Vinca Alkaloid Agents, Podophyllotoxin Derivative Antineoplastic Agents, Antimetabolite Antineoplastic Agents, Anthracycline Antineoplastic Agents, Antimicrotubular Antineoplastics, and Corticosteroids. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of HL that are available in the market.
TechNavio's report, the Global Hodgkin's Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hodgkin's Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ APAC
‧ EMEA
Key Vendors
‧ Bristol Myers Squibb Co.
‧ F. Hoffmann-La Roche Ltd.
‧ Merck & Co. Inc.
‧ Pfizer Inc.
Other Prominent Vendors
‧ 4SC AG
‧ Actinium Pharmaceuticals Inc.
‧ Aeterna Zentaris Inc.
‧ Affimed Therapeutics AG
‧ Hospira Inc.
‧ Incyte Corp.
‧ Novartis AG
‧ Philogen S.p.A.
‧ Seattle Genetics Inc.
‧ Sigma-Tau Pharmaceuticals Inc.
‧ Stemline Therapeutics Inc.
‧ Teva Pharmaceutical Industries Ltd.
Key Market Driver
‧ Improved Diagnostic Techniques.
‧ For a full, detailed list, view our report.
Key Market Challenge
‧ High Cost.
‧ For a full, detailed list, view our report.
Key Market Trend
‧ Increase in Awareness of HL.
‧ For a full, detailed list, view our report.
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
07. WHO Classification of Hodgkin's lymphoma
08. Stages of Hodgkin's Lymphoma
09. Chemotherapy Options for Hodgkin’s Lymphoma
09.1 Five Forces Analysis
10. Market Segmentation by Drug Class
11. Geographical Segmentation
12. Buying Criteria
13. Rate of Incidence and Prevalence
13.1.1 US
13.1.2 UK
14. Pipeline Snapshot
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2013
21.3 Other Prominent Vendors
22. Key Vendor Analysis
22.1 Bristol-Myers Squibb Co.
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Product Segmentation
22.1.4 Sales by Geography
22.1.5 Business Strategy
22.1.6 Key Information
22.1.7 SWOT Analysis
22.1.8 Strengths
22.1.9 Weaknesses
22.1.10 Opportunities
22.1.11 Threats
22.2 F. Hoffmann La Roche Ltd.
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation
22.2.4 Business Segmentation by Revenue 2012 and 2013
22.2.5 Sales by Geography
22.2.6 Business Strategy
22.2.7 Key Information
22.2.8 SWOT Analysis
22.2.9 Strengths
22.2.10 Weaknesses
22.2.11 Opportunities
22.2.12 Threats
22.3 Merck & Co. Inc.
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Business Segmentation by Revenue 2013
22.3.4 Business Segmentation by Revenue 2012 and 2013
22.3.5 Sales by Geography
22.3.6 Business Strategy
22.3.7 Key Developments
22.3.8 SWOT Analysis
22.3.9 Strengths
22.3.10 Weaknesses
22.3.11 Opportunities
22.3.12 Threats
22.4 Pfizer Inc.
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation by Revenue 2013
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Sales by Geography
22.4.6 Business Strategy
22.4.7 Key Developments
22.4.8 SWOT Analysis
22.4.9 Strengths
22.4.10 Weaknesses
22.4.11 Opportunities
22.4.12 Threats
23. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Hodgkin's Lymphoma Therapeutics Market 2013-2018 (US$ million)
Exhibit 3: NCI Lymphoma Research Portfolio 2013
Exhibit 4: Global Hodgkin's Lymphoma Therapeutics Market Segmentation by Drug Class
Exhibit 5: Global Hodgkin's Lymphoma Therapeutics Market by Geographical Segmentation 2013
Exhibit 6: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
Exhibit 7: Bristol-Myers Squibb Co.: Sales by Geography 2013
Exhibit 8: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 9: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
Exhibit 10: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 11: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
Exhibit 12: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 13: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 14: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 15: Pfizer Inc.: Business Segmentation by Revenue 2013
Exhibit 16: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
Exhibit 17: Pfizer Inc.: Sales by Geography 2013
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
07. WHO Classification of Hodgkin's lymphoma
08. Stages of Hodgkin's Lymphoma
09. Chemotherapy Options for Hodgkin’s Lymphoma
09.1 Five Forces Analysis
10. Market Segmentation by Drug Class
11. Geographical Segmentation
12. Buying Criteria
13. Rate of Incidence and Prevalence
13.1.1 US
13.1.2 UK
14. Pipeline Snapshot
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2013
21.3 Other Prominent Vendors
22. Key Vendor Analysis
22.1 Bristol-Myers Squibb Co.
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Product Segmentation
22.1.4 Sales by Geography
22.1.5 Business Strategy
22.1.6 Key Information
22.1.7 SWOT Analysis
22.1.8 Strengths
22.1.9 Weaknesses
22.1.10 Opportunities
22.1.11 Threats
22.2 F. Hoffmann La Roche Ltd.
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation
22.2.4 Business Segmentation by Revenue 2012 and 2013
22.2.5 Sales by Geography
22.2.6 Business Strategy
22.2.7 Key Information
22.2.8 SWOT Analysis
22.2.9 Strengths
22.2.10 Weaknesses
22.2.11 Opportunities
22.2.12 Threats
22.3 Merck & Co. Inc.
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Business Segmentation by Revenue 2013
22.3.4 Business Segmentation by Revenue 2012 and 2013
22.3.5 Sales by Geography
22.3.6 Business Strategy
22.3.7 Key Developments
22.3.8 SWOT Analysis
22.3.9 Strengths
22.3.10 Weaknesses
22.3.11 Opportunities
22.3.12 Threats
22.4 Pfizer Inc.
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation by Revenue 2013
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Sales by Geography
22.4.6 Business Strategy
22.4.7 Key Developments
22.4.8 SWOT Analysis
22.4.9 Strengths
22.4.10 Weaknesses
22.4.11 Opportunities
22.4.12 Threats
23. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Hodgkin's Lymphoma Therapeutics Market 2013-2018 (US$ million)
Exhibit 3: NCI Lymphoma Research Portfolio 2013
Exhibit 4: Global Hodgkin's Lymphoma Therapeutics Market Segmentation by Drug Class
Exhibit 5: Global Hodgkin's Lymphoma Therapeutics Market by Geographical Segmentation 2013
Exhibit 6: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
Exhibit 7: Bristol-Myers Squibb Co.: Sales by Geography 2013
Exhibit 8: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 9: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
Exhibit 10: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 11: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
Exhibit 12: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 13: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 14: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 15: Pfizer Inc.: Business Segmentation by Revenue 2013
Exhibit 16: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
Exhibit 17: Pfizer Inc.: Sales by Geography 2013
